Special Issue

Antibody-Based Therapeutics Against COVID-19

Message from the Guest Editor

An emerging coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease known as COVID-19. To date, SARS-CoV-2 continues to rapidly spread globally and seriously threaten public health. Therapeutic antibodies are shown to be very effective in the treatment of various diseases, including viral infection and immune disorder. Clinical trials with antibody-based drugs for COVID-19 are being performed all over the world. Some of them are quite promising. For example, Bamlanivimab, a neutralizing antibody against SARS-CoV-2, was authorized by the FDA for the treatment of COVID-19 in high-risk patients on November 9, 2020. This Special Issue will collect the last progress on antibody-based therapeutics against COVID-19 from bench to bedside.

Guest Editor

Prof. Dr. Rui Gong

Center for Antiviral Research, Wuhan Institute of Virology (WIV), Chinese Academy of Sciences, 262 Jinlong Street, Jiangxia, Wuhan 430207, China

Deadline for manuscript submissions

closed (20 September 2021)



an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



mdpi.com/si/76236

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/ antibodies





an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

